LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer
Mark brings 30 years of experience in R&D spanning discovery to late-stage clinical development London, 7 April 2025 – LIfT BioSciences,...
Apr 7
Dr Michael McCarthy discusses one of the biggest challenges in solid tumour treatment: treatment resistance
We spoke to Dr Michael McCarthy, Consultant Medical Oncologist at University Hospital Galway, regarding what treatment resistance in...
Apr 3
LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics
Access to extensive donor pool supports LIfT’s move into the clinic London, 03 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’),...
Apr 3
Our CEO Alex Blyth discusses what makes LIfT’s IMANs different
To kick LIfT’s science series off, we spoke to our CEO Alex Blyth regarding what makes IMANs different to regular neutrophils, what were...
Mar 20
LIfT BioSciences Secures Another Landmark US Patent, Strengthening Its Position as the World Leader in Neutrophil Immunotherapies
London, 13 March 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...
Mar 13
